Solanezumab

Solanezumab is a monoclonal antibody designed for the treatment of Alzheimer's disease. Developed by Eli Lilly and Company, Solanezumab was created to recognize and bind to the amyloid-β peptides that accumulate in the brains of Alzheimer's patients.

Development and Clinical Trials[edit | edit source]

Solanezumab was developed by Eli Lilly and Company as a potential treatment for Alzheimer's disease. The drug is a monoclonal antibody that targets amyloid-β peptides, which are believed to play a key role in the development of Alzheimer's disease.

In 2016, results from a large-scale clinical trial known as EXPEDITION3 were published. The trial did not meet its primary endpoint, which was a significant slowing of cognitive decline in patients with mild Alzheimer's disease. However, some secondary analyses suggested that Solanezumab might have a modest effect on slowing cognitive decline in this patient population.

Mechanism of Action[edit | edit source]

Solanezumab is designed to bind to amyloid-β peptides in the brain. These peptides are a primary component of the amyloid plaques that are a hallmark of Alzheimer's disease. By binding to these peptides, Solanezumab is thought to facilitate their removal from the brain, thereby potentially slowing the progression of the disease.

Future Research[edit | edit source]

Despite the disappointing results of the EXPEDITION3 trial, research into Solanezumab and other amyloid-targeting therapies continues. Some researchers believe that treating patients earlier in the course of their disease, before significant brain damage has occurred, may yield more positive results.